2013 Form 10-K Financial Statement
#000114420414018406 Filed on March 27, 2014
Income Statement
| Concept | 2013 | 2012 Q4 | 2012 Q3 |
|---|---|---|---|
| Revenue | $25.03M | $9.079M | $5.415M |
| YoY Change | 11.72% | 21.7% | 6.59% |
| Cost Of Revenue | $8.361M | $3.390M | $2.020M |
| YoY Change | 2.54% | 27.44% | 35.57% |
| Gross Profit | $16.67M | $5.688M | $3.399M |
| YoY Change | 16.97% | 18.5% | -5.58% |
| Gross Profit Margin | 66.6% | 62.65% | 62.77% |
| Selling, General & Admin | $15.43M | $6.020M | $2.160M |
| YoY Change | 2.38% | -1.95% | -5.68% |
| % of Gross Profit | 92.56% | 105.84% | 63.55% |
| Research & Development | $824.0K | $250.0K | $170.0K |
| YoY Change | -36.66% | -48.98% | -15.0% |
| % of Gross Profit | 4.94% | 4.4% | 5.0% |
| Depreciation & Amortization | $243.0K | $60.00K | $70.00K |
| YoY Change | -3.57% | 0.0% | -36.36% |
| % of Gross Profit | 1.46% | 1.05% | 2.06% |
| Operating Expenses | $16.26M | $6.260M | $2.320M |
| YoY Change | 5.9% | -5.58% | -6.83% |
| Operating Profit | $416.0K | -$572.0K | $1.079M |
| YoY Change | -137.89% | -68.74% | -2.79% |
| Interest Expense | $13.00K | $0.00 | $0.00 |
| YoY Change | |||
| % of Operating Profit | 3.13% | 0.0% | |
| Other Income/Expense, Net | |||
| YoY Change | |||
| Pretax Income | $405.0K | $450.0K | $1.070M |
| YoY Change | -137.12% | -124.59% | -3.6% |
| Income Tax | $0.00 | $0.00 | $0.00 |
| % Of Pretax Income | 0.0% | 0.0% | 0.0% |
| Net Earnings | $405.0K | $453.0K | $1.074M |
| YoY Change | -137.12% | -124.75% | -3.24% |
| Net Earnings / Revenue | 1.62% | 4.99% | 19.83% |
| Basic Earnings Per Share | $0.03 | $0.07 | |
| Diluted Earnings Per Share | $0.03 | $30.18K | $0.07 |
| COMMON SHARES | |||
| Basic Shares Outstanding | 15.84M shares | 14.84M shares | |
| Diluted Shares Outstanding | 16.28M shares | 14.98M shares |
Balance Sheet
| Concept | 2013 | 2012 Q4 | 2012 Q3 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $1.640M | $570.0K | $1.820M |
| YoY Change | 187.72% | -89.71% | -60.61% |
| Cash & Equivalents | $1.640M | $572.0K | $1.815M |
| Short-Term Investments | |||
| Other Short-Term Assets | $1.800M | $2.690M | $1.100M |
| YoY Change | -33.09% | 53.71% | -40.22% |
| Inventory | $2.520M | $2.051M | $3.410M |
| Prepaid Expenses | |||
| Receivables | $5.320M | $5.409M | $4.170M |
| Other Receivables | $0.00 | $0.00 | $0.00 |
| Total Short-Term Assets | $11.28M | $10.72M | $10.51M |
| YoY Change | 5.22% | -18.8% | -26.96% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $2.560M | $2.365M | $2.450M |
| YoY Change | 8.02% | 2.38% | 4.26% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | |||
| YoY Change | |||
| Total Long-Term Assets | $6.140M | $5.942M | $6.020M |
| YoY Change | 3.37% | 1.05% | 1.52% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $11.28M | $10.72M | $10.51M |
| Total Long-Term Assets | $6.140M | $5.942M | $6.020M |
| Total Assets | $17.42M | $16.66M | $16.53M |
| YoY Change | 4.56% | -12.68% | -18.65% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $1.010M | $1.296M | $540.0K |
| YoY Change | -22.31% | 45.62% | -26.03% |
| Accrued Expenses | $2.850M | $2.760M | $5.670M |
| YoY Change | -13.9% | -57.41% | -11.96% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | |||
| YoY Change | |||
| Total Short-Term Liabilities | $4.620M | $4.910M | $6.640M |
| YoY Change | -5.91% | -37.45% | -12.29% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Other Long-Term Liabilities | $200.0K | $300.0K | |
| YoY Change | -33.33% | ||
| Total Long-Term Liabilities | $200.0K | $300.0K | $0.00 |
| YoY Change | -33.33% | ||
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $4.620M | $4.910M | $6.640M |
| Total Long-Term Liabilities | $200.0K | $300.0K | $0.00 |
| Total Liabilities | $4.820M | $5.210M | $6.640M |
| YoY Change | -7.49% | -33.63% | -12.29% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$5.790M | ||
| YoY Change | |||
| Common Stock | $42.88M | ||
| YoY Change | |||
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | $25.64M | ||
| YoY Change | |||
| Treasury Stock Shares | 5.336M shares | ||
| Shareholders Equity | $12.60M | $11.45M | $9.890M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $17.42M | $16.66M | $16.53M |
| YoY Change | 4.56% | -12.68% | -18.65% |
Cashflow Statement
| Concept | 2013 | 2012 Q4 | 2012 Q3 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | $405.0K | $453.0K | $1.074M |
| YoY Change | -137.12% | -124.75% | -3.24% |
| Depreciation, Depletion And Amortization | $243.0K | $60.00K | $70.00K |
| YoY Change | -3.57% | 0.0% | -36.36% |
| Cash From Operating Activities | $1.140M | -$2.340M | -$2.690M |
| YoY Change | -119.9% | -348.94% | -25.28% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $442.0K | $20.00K | -$100.0K |
| YoY Change | 42.58% | -300.0% | 11.11% |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Cash From Investing Activities | -$440.0K | $20.00K | -$100.0K |
| YoY Change | 41.94% | -300.0% | 25.0% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | $444.0K | ||
| YoY Change | -58.5% | ||
| Debt Paid & Issued, Net | $100.0K | ||
| YoY Change | |||
| Cash From Financing Activities | 370.0K | 1.070M | 0.000 |
| YoY Change | -65.42% | -100.0% | |
| NET CHANGE | |||
| Cash From Operating Activities | 1.140M | -2.340M | -2.690M |
| Cash From Investing Activities | -440.0K | 20.00K | -100.0K |
| Cash From Financing Activities | 370.0K | 1.070M | 0.000 |
| Net Change In Cash | 1.070M | -1.250M | -2.790M |
| YoY Change | -121.53% | -234.41% | -32.45% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | $1.140M | -$2.340M | -$2.690M |
| Capital Expenditures | $442.0K | $20.00K | -$100.0K |
| Free Cash Flow | $698.0K | -$2.360M | -$2.590M |
| YoY Change | -111.56% | -348.42% | -26.21% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2013 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <h2 style="PAGE-BREAK-AFTER: auto; MARGIN: 0in 0in 0pt"><u><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: normal"> <i>Use of Estimates</i></font></u></h2> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The preparation of financial statements and the accompanying notes thereto, in conformity with generally accepted accounting principles in the United States (“GAAP”), requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets <font style="COLOR: black">and liabilities</font> at the date of the financial statements and reported amounts of revenues and expenses during the respective reporting periods.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font> Examples include the provision for bad debt, sales returns and allowances, inventory obsolescence, useful lives of property and equipment and intangible assets, impairment of property and equipment and intangible assets, income tax valuations and assumptions related to accrued advertising.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font> When providing for the appropriate sales returns, allowances, cash discounts and cooperative incentive promotion costs (“Sales Allowances”), we apply a uniform and consistent method for making certain assumptions for estimating these provisions.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font> These estimates and assumptions are based on historical experience, current trends and other factors that management believes to be relevant at the time the financial statements are prepared.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font> Management reviews the accounting policies, assumptions, estimates and judgments on a quarterly basis.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font> Actual results could differ from those estimates.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Our primary product, Cold-EEZE</font><sup><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Ò</font></font></sup><sup> <font style="FONT-SIZE: 10pt"></font></sup><font style="FONT-SIZE: 10pt">Cold Remedy lozenges, utilizes a proprietary zinc gluconate formulation which has been clinically proven to reduce the severity and duration of common cold symptoms.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font> Factors considered in estimating the appropriate sales returns and allowances for this product include it being (i) a unique product with limited competitors, (ii) competitively priced, (iii) promoted, (iv) unaffected for remaining shelf-life as there is no product expiration date and (v) monitored for inventory levels at major customers and third-party consumption data.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font> In addition to Cold-EEZE<sup>®</sup> Cold Remedy lozenges, we market and distribute a variety of Cold-EEZE<sup>®</sup> Cold Remedy QuickMelts<sup>®</sup> and a Cold-EEZE<sup>®</sup> Cold Remedy Oral Spray.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font> We also manufacture, market and distribute an organic cough drop and a Vitamin C supplement (“Organix<sup>®</sup>”).<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font> Each of the Cold-EEZE<sup>®</sup> Cold Remedy Oral Spray and QuickMelts<sup>®</sup> products, and Organix<sup>®</sup> products carry shelf-life expiration dates for which we aggregate such new product market experience data and update our sales returns and allowances estimates accordingly.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font> Sales allowances estimates are tracked at the specific customer and product line levels and are tested on an annual historical basis, and reviewed quarterly. Additionally, we monitor current developments by customer, market conditions and any other occurrences that could affect the expected provisions relative to net sales for the period presented.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | |
| CY2013 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><u><font style="FONT-SIZE: 10pt">Concentration of Risks</font></u></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Future revenues, costs, margins and profits will continue to be influenced by our ability to maintain our manufacturing availability and capacity together with our marketing and distribution capabilities and the requirements associated with the development of OTC and other personal care products in order to continue to compete on a national and/or international level.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Our business is subject to federal and state laws and regulations adopted for the health and safety of users of our products. Our OTC cold remedy products are subject to regulations by various federal, state and local agencies, including the Food and Drug Administration (“FDA”) and, as applicable, the Homeopathic Pharmacopoeia of the United States.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Financial instruments that potentially subject us to significant concentrations of credit risk consist principally of cash investments and trade accounts receivable.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">We maintain cash and cash equivalents with certain major financial institutions. As of December 31, 2013, our cash was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.6</font> million and our bank balance was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.8</font> million. Of the total bank balance, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">554,000</font> was covered by federal depository insurance and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.2</font> million was uninsured.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Trade accounts receivable potentially subjects us to credit risk.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font> We extend credit to our customers based upon an evaluation of the customer’s financial condition and credit history and generally we do not require collateral. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">  </font> Our broad range of customers includes many <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">national chain, regional, specialty and local retail stores </font> (see Note 11).<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font> During Fiscal 2013, 2012 and 2011, effectively all of our net revenues were related to domestic markets.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Our revenues are principally generated from the sale of OTC cold remedy products which approximated <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 94</font>%, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 95</font>% and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 95</font>% of total revenues for Fiscal 2013, 2012 and 2011, respectively.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">A significant portion of our business is highly seasonal, which causes major variations in operating results from quarter to quarter.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font> The third and fourth quarters generally represent the largest sales volume for the OTC cold remedy products.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Raw materials used in the production of the products are available from numerous sources.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Certain raw material active ingredients used in connection with Cold-EEZE<sup>®</sup> Cold Remedy products are purchased from a single unaffiliated supplier.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font> Should the relationship terminate or the vendor become unable supply material, we believe that the current contingency plans would prevent a termination from materially affecting our operations.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font> However, if the relationship was terminated, there may be delays in production of our products until an acceptable replacement supplier is located.</font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | |
| CY2012Q4 | us-gaap |
Inventory Work In Process And Raw Materials
InventoryWorkInProcessAndRawMaterials
|
1000000 | USD |
| CY2012Q4 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
1000000 | USD |
| CY2012 | us-gaap |
Sales Allowances Goods
SalesAllowancesGoods
|
109000 | USD |
| CY2013 | us-gaap |
Sales Allowances Goods
SalesAllowancesGoods
|
128000 | USD |
| CY2011 | us-gaap |
Marketing And Advertising Expense
MarketingAndAdvertisingExpense
|
8800000 | USD |
| CY2011 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-2710000 | USD |
| CY2013 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
405000 | USD |
| CY2011 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
14817000 | shares |
| CY2012 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
14843000 | shares |
| CY2013 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
15839000 | shares |
| CY2013 | prph |
Entity Principal Product Proven Efficiency Percentage Description
EntityPrincipalProductProvenEfficiencyPercentageDescription
|
Our flagship brand is Cold-EEZE Cold Remedy and our principal product is Cold-EEZE Cold Remedy zinc gluconate lozenges, proven in clinical studies to reduce the duration of the common cold by 42% | |
| CY2013Q4 | us-gaap |
Cash Fdic Insured Amount
CashFDICInsuredAmount
|
554000 | USD |
| CY2013Q4 | us-gaap |
Cash Uninsured Amount
CashUninsuredAmount
|
1200000 | USD |
| CY2013Q4 | us-gaap |
Inventory Work In Process And Raw Materials
InventoryWorkInProcessAndRawMaterials
|
1600000 | USD |
| CY2013Q4 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
958000 | USD |
| CY2013Q4 | us-gaap |
Due From Banks
DueFromBanks
|
1800000 | USD |
| CY2011 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
631000 | USD |
| CY2012 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
246000 | USD |
| CY2013 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
269000 | USD |
| CY2010Q1 | us-gaap |
Variable Interest Entity Ownership Percentage
VariableInterestEntityOwnershipPercentage
|
0.5 | pure |
| CY2012 | us-gaap |
Marketing And Advertising Expense
MarketingAndAdvertisingExpense
|
10200000 | USD |
| CY2013 | us-gaap |
Marketing And Advertising Expense
MarketingAndAdvertisingExpense
|
10800000 | USD |
| CY2013Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0005 | |
| CY2013Q4 | us-gaap |
Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
|
1125000 | USD |
| CY2013Q4 | us-gaap |
Contractual Obligation Due In Second Year
ContractualObligationDueInSecondYear
|
655000 | USD |
| CY2013Q4 | us-gaap |
Contractual Obligation Due In Third Year
ContractualObligationDueInThirdYear
|
100000 | USD |
| CY2013Q4 | us-gaap |
Contractual Obligation Due In Fourth Year
ContractualObligationDueInFourthYear
|
0 | USD |
| CY2013Q4 | us-gaap |
Contractual Obligation Due In Fifth Year
ContractualObligationDueInFifthYear
|
0 | USD |
| CY2013Q4 | us-gaap |
Contractual Obligation Due After Fifth Year
ContractualObligationDueAfterFifthYear
|
1880000 | USD |
| CY2012Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
572000 | USD |
| CY2013Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
1638000 | USD |
| CY2012Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
5409000 | USD |
| CY2013Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
5319000 | USD |
| CY2012Q4 | us-gaap |
Inventory Net
InventoryNet
|
2051000 | USD |
| CY2013Q4 | us-gaap |
Inventory Net
InventoryNet
|
2521000 | USD |
| CY2012Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
2687000 | USD |
| CY2013Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
1801000 | USD |
| CY2012Q4 | us-gaap |
Assets Current
AssetsCurrent
|
10719000 | USD |
| CY2013Q4 | us-gaap |
Assets Current
AssetsCurrent
|
11279000 | USD |
| CY2012Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
2365000 | USD |
| CY2013Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
2564000 | USD |
| CY2012Q4 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
3577000 | USD |
| CY2013Q4 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
3577000 | USD |
| CY2012Q4 | us-gaap |
Assets
Assets
|
16661000 | USD |
| CY2013Q4 | us-gaap |
Assets
Assets
|
17420000 | USD |
| CY2012Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
1296000 | USD |
| CY2013Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
1011000 | USD |
| CY2012Q4 | us-gaap |
Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
|
2760000 | USD |
| CY2013Q4 | us-gaap |
Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
|
2847000 | USD |
| CY2012Q4 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
854000 | USD |
| CY2013Q4 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
766000 | USD |
| CY2012Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
4910000 | USD |
| CY2013Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
4624000 | USD |
| CY2012Q4 | us-gaap |
Liabilities Other Than Longterm Debt Noncurrent
LiabilitiesOtherThanLongtermDebtNoncurrent
|
300000 | USD |
| CY2013Q4 | us-gaap |
Liabilities Other Than Longterm Debt Noncurrent
LiabilitiesOtherThanLongtermDebtNoncurrent
|
200000 | USD |
| CY2012Q4 | us-gaap |
Liabilities Noncurrent
LiabilitiesNoncurrent
|
300000 | USD |
| CY2013Q4 | us-gaap |
Liabilities Noncurrent
LiabilitiesNoncurrent
|
200000 | USD |
| CY2012Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2013Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2012Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
11000 | USD |
| CY2013Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
11000 | USD |
| CY2012Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
42867000 | USD |
| CY2013Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
43607000 | USD |
| CY2012Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-5790000 | USD |
| CY2013Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-5385000 | USD |
| CY2012Q4 | us-gaap |
Treasury Stock Value
TreasuryStockValue
|
25637000 | USD |
| CY2013Q4 | us-gaap |
Treasury Stock Value
TreasuryStockValue
|
25637000 | USD |
| CY2012Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
11451000 | USD |
| CY2013Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
12596000 | USD |
| CY2012Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
16661000 | USD |
| CY2013Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
17420000 | USD |
| CY2012Q4 | us-gaap |
Payments For Legal Settlements
PaymentsForLegalSettlements
|
2100000 | USD |
| CY2013Q4 | prph |
Additional Royalties And Commissions Accrual Interest Percentage
AdditionalRoyaltiesAndCommissionsAccrualInterestPercentage
|
0.0325 | pure |
| CY2013 | prph |
Additional Royalties And Commissions Payable Installment Amount
AdditionalRoyaltiesAndCommissionsPayableInstallmentAmount
|
100000 | USD |
| CY2012Q4 | prph |
Additional Royalties And Commissions Payable Installment Amount
AdditionalRoyaltiesAndCommissionsPayableInstallmentAmount
|
100000 | USD |
| CY2012Q4 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
3500000 | USD |
| CY2013Q4 | prph |
Additional Annual Installment Includes In Other Current Liability
AdditionalAnnualInstallmentIncludesInOtherCurrentLiability
|
100000 | USD |
| CY2012 | prph |
Maximum Number Of Common Stock Authorized For Issuance Over36 Months
MaximumNumberOfCommonStockAuthorizedForIssuanceOver36Months
|
2500000 | shares |
| CY2013 | prph |
Maximum Amount Entitled To Put To Investor In One Draw Down Notice Percentage Of Average Daily Volume On Trading Day
MaximumAmountEntitledToPutToInvestorInOneDrawDownNoticePercentageOfAverageDailyVolumeOnTradingDay
|
5 | pure |
| CY2013 | prph |
Maximum Amount Entitled To Put To Investor In One Draw Down Notice
MaximumAmountEntitledToPutToInvestorInOneDrawDownNotice
|
250000 | USD |
| CY2013 | prph |
Investor Right To Use Excess Proceeds Maximum Percentage
InvestorRightToUseExcessProceedsMaximumPercentage
|
0.05 | pure |
| CY2013 | prph |
Share Purchase Put Restrictions Maximum Percentage Of Ownership Held By Investor To Purchase Shares In Equity Line Of Credit
SharePurchasePutRestrictionsMaximumPercentageOfOwnershipHeldByInvestorToPurchaseSharesInEquityLineOfCredit
|
0.0999 | pure |
| CY2013Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
|
1600000 | shares |
| CY2013 | prph |
Dilutive Securities Options Earnings Per Share Value
DilutiveSecuritiesOptionsEarningsPerShareValue
|
0 | USD |
| CY2013 | prph |
Equity Method Investment Ownership Percentage Required For Rights Exercisable Under Right Agreement
EquityMethodInvestmentOwnershipPercentageRequiredForRightsExercisableUnderRightAgreement
|
0.15 | pure |
| CY2009Q3 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
|
45 | |
| CY2012Q4 | prph |
Equity Line Purchase Price Percentage
EquityLinePurchasePricePercentage
|
0.95 | pure |
| CY2013Q4 | prph |
Deferred Tax Benefits From Options And Warrants Exercises
DeferredTaxBenefitsFromOptionsAndWarrantsExercises
|
6500000 | USD |
| CY2010 | prph |
Payments To Fund Joint Venture Investments
PaymentsToFundJointVentureInvestments
|
500000 | USD |
| CY2010 | prph |
Maximum Amount Committed Towards Contributions In Joint Venture
MaximumAmountCommittedTowardsContributionsInJointVenture
|
2000000 | USD |
| CY2013 | prph |
Ownership Percentage In Joint Venture
OwnershipPercentageInJointVenture
|
0.5 | pure |
| CY2012 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-1091000 | USD |
| CY2011 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.18 | |
| CY2012 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.07 | |
| CY2013 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.03 | |
| CY2011 | prph |
Dilutive Securities Options Earnings Per Share Value
DilutiveSecuritiesOptionsEarningsPerShareValue
|
0 | USD |
| CY2012 | prph |
Dilutive Securities Options Earnings Per Share Value
DilutiveSecuritiesOptionsEarningsPerShareValue
|
0 | USD |
| CY2011 | prph |
Dilutive Securities Options Earnings Share
DilutiveSecuritiesOptionsEarningsShare
|
0 | shares |
| CY2012 | prph |
Dilutive Securities Options Earnings Share
DilutiveSecuritiesOptionsEarningsShare
|
0 | shares |
| CY2013 | prph |
Dilutive Securities Options Earnings Share
DilutiveSecuritiesOptionsEarningsShare
|
437000 | shares |
| CY2011 | prph |
Dilutive Securities Options Earnings Per Share
DilutiveSecuritiesOptionsEarningsPerShare
|
0 | |
| CY2012 | prph |
Dilutive Securities Options Earnings Per Share
DilutiveSecuritiesOptionsEarningsPerShare
|
0 | |
| CY2013 | prph |
Dilutive Securities Options Earnings Per Share
DilutiveSecuritiesOptionsEarningsPerShare
|
0 | |
| CY2011 | us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
-2710000 | USD |
| CY2012 | us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
-1091000 | USD |
| CY2013 | us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
405000 | USD |
| CY2011 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.18 | |
| CY2012 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.07 | |
| CY2013 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.03 | |
| CY2012Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
3860000 | USD |
| CY2013Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
4064000 | USD |
| CY2012Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0005 | |
| CY2012Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
50000000 | shares |
| CY2013Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
50000000 | shares |
| CY2012Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
21056115 | shares |
| CY2013Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
21437059 | shares |
| CY2012Q4 | us-gaap |
Treasury Stock Shares
TreasuryStockShares
|
5336053 | shares |
| CY2013Q4 | us-gaap |
Treasury Stock Shares
TreasuryStockShares
|
5336053 | shares |
| CY2011 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
17453000 | USD |
| CY2012 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
22406000 | USD |
| CY2013 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
25032000 | USD |
| CY2011 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
6171000 | USD |
| CY2012 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
8154000 | USD |
| CY2013 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
8361000 | USD |
| CY2011 | us-gaap |
Gross Profit
GrossProfit
|
11282000 | USD |
| CY2012 | us-gaap |
Gross Profit
GrossProfit
|
14252000 | USD |
| CY2013 | us-gaap |
Gross Profit
GrossProfit
|
16671000 | USD |
| CY2011 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
7904000 | USD |
| CY2012 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
8946000 | USD |
| CY2013 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
9538000 | USD |
| CY2011 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
5028000 | USD |
| CY2012 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
6127000 | USD |
| CY2013 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
5893000 | USD |
| CY2011 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
1088000 | USD |
| CY2012 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
1301000 | USD |
| CY2013 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
824000 | USD |
| CY2011 | us-gaap |
Operating Expenses
OperatingExpenses
|
14020000 | USD |
| CY2012 | us-gaap |
Operating Expenses
OperatingExpenses
|
15350000 | USD |
| CY2013 | us-gaap |
Operating Expenses
OperatingExpenses
|
16255000 | USD |
| CY2011 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-2738000 | USD |
| CY2012 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-1098000 | USD |
| CY2013 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
1066000 | USD |
| CY2011Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
5541000 | USD |
| CY2012 | us-gaap |
Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
|
0 | USD |
| CY2013 | us-gaap |
Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
|
0 | USD |
| CY2013 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
416000 | USD |
| CY2011 | us-gaap |
Interest And Other Income
InterestAndOtherIncome
|
28000 | USD |
| CY2012 | us-gaap |
Interest And Other Income
InterestAndOtherIncome
|
7000 | USD |
| CY2013 | us-gaap |
Interest And Other Income
InterestAndOtherIncome
|
2000 | USD |
| CY2011 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-2710000 | USD |
| CY2012 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-1091000 | USD |
| CY2013 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
405000 | USD |
| CY2011 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | USD |
| CY2012 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | USD |
| CY2013 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | USD |
| CY2011 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-2710000 | USD |
| CY2012 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-1091000 | USD |
| CY2013 | us-gaap |
Net Income Loss
NetIncomeLoss
|
405000 | USD |
| CY2011 | us-gaap |
Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
|
-0.18 | |
| CY2012 | us-gaap |
Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
|
-0.07 | |
| CY2013 | us-gaap |
Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
|
0.03 | |
| CY2011 | us-gaap |
Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
|
-0.18 | |
| CY2012 | us-gaap |
Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
|
-0.07 | |
| CY2013 | us-gaap |
Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
|
0.03 | |
| CY2010Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
13460000 | USD |
| CY2013 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
27000 | USD |
| CY2011 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
131000 | USD |
| CY2012 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
153000 | USD |
| CY2013 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
160000 | USD |
| CY2011 | us-gaap |
Stock Granted During Period Value Sharebased Compensation Gross
StockGrantedDuringPeriodValueSharebasedCompensationGross
|
500000 | USD |
| CY2013 | us-gaap |
Stock Granted During Period Value Sharebased Compensation Gross
StockGrantedDuringPeriodValueSharebasedCompensationGross
|
109000 | USD |
| CY2012 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
1070000 | USD |
| CY2013 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
444000 | USD |
| CY2011Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
11226000 | USD |
| CY2011 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
355000 | USD |
| CY2012 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
252000 | USD |
| CY2013 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
243000 | USD |
| CY2011 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-1602000 | USD |
| CY2012 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
2190000 | USD |
| CY2013 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-90000 | USD |
| CY2011 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
1006000 | USD |
| CY2012 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
-637000 | USD |
| CY2013 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
470000 | USD |
| CY2011 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
396000 | USD |
| CY2012 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
411000 | USD |
| CY2013 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-285000 | USD |
| CY2011 | prph |
Increase Decrease In Accrued Marketing Costs
IncreaseDecreaseInAccruedMarketingCosts
|
-565000 | USD |
| CY2012 | prph |
Increase Decrease In Accrued Marketing Costs
IncreaseDecreaseInAccruedMarketingCosts
|
-199000 | USD |
| CY2013 | prph |
Increase Decrease In Accrued Marketing Costs
IncreaseDecreaseInAccruedMarketingCosts
|
87000 | USD |
| CY2011 | us-gaap |
Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
|
-81000 | USD |
| CY2012 | us-gaap |
Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
|
-269000 | USD |
| CY2013 | us-gaap |
Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
|
88000 | USD |
| CY2011 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-2108000 | USD |
| CY2012 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-5729000 | USD |
| CY2013 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
1137000 | USD |
| CY2011 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
300000 | USD |
| CY2012 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
310000 | USD |
| CY2013 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-442000 | USD |
| CY2011 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
0 | USD |
| CY2012 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
0 | USD |
| CY2013 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
27000 | USD |
| CY2011 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
0 | USD |
| CY2013 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
442000 | USD |
| CY2011 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-134000 | USD |
| CY2012 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-310000 | USD |
| CY2012 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
1070000 | USD |
| CY2013 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
444000 | USD |
| CY2011 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
-449000 | USD |
| CY2013 | us-gaap |
Payments For Repurchase Of Equity
PaymentsForRepurchaseOfEquity
|
0 | USD |
| CY2011 | us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
0 | USD |
| CY2012 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
1070000 | USD |
| CY2013 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
371000 | USD |
| CY2011 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-2691000 | USD |
| CY2012 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-4969000 | USD |
| CY2010Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
8232000 | USD |
| CY2011 | prph |
Settlement Benefit
SettlementBenefit
|
0 | USD |
| CY2012 | prph |
Settlement Benefit
SettlementBenefit
|
1024000 | USD |
| CY2013 | prph |
Settlement Benefit
SettlementBenefit
|
0 | USD |
| CY2011 | prph |
Stock Granted During Period Value Employment Agreement
StockGrantedDuringPeriodValueEmploymentAgreement
|
294000 | USD |
| CY2012 | prph |
Stock Granted During Period Value Employment Agreement
StockGrantedDuringPeriodValueEmploymentAgreement
|
93000 | USD |
| CY2011 | us-gaap |
Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
|
449000 | USD |
| CY2011 | us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
28000 | USD |
| CY2012 | us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
0 | USD |
| CY2013 | us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
0 | USD |
| CY2011 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
864000 | USD |
| CY2012 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
940000 | USD |
| CY2013 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-886000 | USD |
| CY2011 | us-gaap |
Increase Decrease In Royalties Payable
IncreaseDecreaseInRoyaltiesPayable
|
0 | USD |
| CY2012 | us-gaap |
Increase Decrease In Royalties Payable
IncreaseDecreaseInRoyaltiesPayable
|
-2100000 | USD |
| CY2013 | us-gaap |
Increase Decrease In Royalties Payable
IncreaseDecreaseInRoyaltiesPayable
|
0 | USD |
| CY2011 | us-gaap |
Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
|
166000 | USD |
| CY2011 | us-gaap |
Payments For Repurchase Of Equity
PaymentsForRepurchaseOfEquity
|
449000 | USD |
| CY2012 | us-gaap |
Payments For Repurchase Of Equity
PaymentsForRepurchaseOfEquity
|
0 | USD |
| CY2012 | us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
0 | USD |
| CY2013 | us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
0 | USD |
| CY2011 | us-gaap |
Stock Issued1
StockIssued1
|
294000 | USD |
| CY2012 | us-gaap |
Stock Issued1
StockIssued1
|
0 | USD |
| CY2013 | us-gaap |
Stock Issued1
StockIssued1
|
0 | USD |
| CY2012Q4 | us-gaap |
Inventory Adjustments
InventoryAdjustments
|
890000 | USD |
| CY2013Q4 | us-gaap |
Inventory Adjustments
InventoryAdjustments
|
635000 | USD |
| CY2012Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
6225000 | USD |
| CY2013Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
6628000 | USD |
| CY2011 | us-gaap |
Depreciation
Depreciation
|
355000 | USD |
| CY2012 | us-gaap |
Depreciation
Depreciation
|
252000 | USD |
| CY2013 | us-gaap |
Depreciation
Depreciation
|
243000 | USD |
| CY2013 | prph |
Employment Agreements Clauses Of Noncompetition Restrictions Description
EmploymentAgreementsClausesOfNoncompetitionRestrictionsDescription
|
Each executive is subject to non-competition restrictions for up to a period of either six (6) months or eighteen (18) months following termination of employment depending on the nature of the termination. Each executive is also eligible for a gross up payment in the event that any amounts payable under the agreements (or any other plan, program, policy or arrangement with the Company) become subject to the excise tax imposed by Section 4999 of the Internal Revenue Code. The Employment Agreements also provide for payments upon certain terminations and change in control benefits to ensure that they work to secure the best outcome for stockholders in the event of a possible change in control, even if it means that they lose their jobs as a result. Under the Employment Agreements, in the event of the termination by the Company of the employment of Mr. Karkus or Mr. Cuddihy without cause or due to a voluntary resignation by either executive with Good Reason (as defined in the agreements), each executive will be paid a lump sum severance payment in cash equal to the greater of (A) the amount equal to eighteen (18) months base salary or (B) the amount equal to the his base salary for the remainder of the term as if the agreement had not been terminated. Additionally, each executive is entitled to receive a lump sum severance payment in cash equal to the greater of A or B, if he, within twenty four (24) months of a Change in Control (as defined in the agreements) of the Company, is terminated without cause or due to a voluntary resignation by him with Good Reason (as defined in the agreements). Each executive may also participate at Company expense in all medical and dental plans for the remainder of the term of his employment agreement in the event the Company terminates the employment agreement for any reason, except for the Companys termination for Cause (as defined in the agreements) or a voluntary resignation by him without Good Reason (as defined in the agreements). | |
| CY2012Q3 | prph |
Defendants Percentage Of Ownership Held By Former Officers And Directors
DefendantsPercentageOfOwnershipHeldByFormerOfficersAndDirectors
|
0.174 | pure |
| CY2010Q3 | prph |
Defendants Percentage Of Ownership Held By Former Officers And Directors
DefendantsPercentageOfOwnershipHeldByFormerOfficersAndDirectors
|
0.174 | pure |
| CY2013Q4 | prph |
Additional Annual Installment Includes In Other Long Term Obligation
AdditionalAnnualInstallmentIncludesInOtherLongTermObligation
|
200000 | USD |
| CY2011 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
220000 | shares |
| CY2012 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
15000 | shares |
| CY2013 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
420500 | shares |
| CY2011 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
|
P4Y | |
| CY2012 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
|
P3Y | |
| CY2011 | prph |
Maximum Term Of Option From Date Of Grant
MaximumTermOfOptionFromDateOfGrant
|
P7Y | |
| CY2012 | prph |
Maximum Term Of Option From Date Of Grant
MaximumTermOfOptionFromDateOfGrant
|
P7Y | |
| CY2012 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
1.36 | |
| CY2011 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
0.58 | |
| CY2012 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
0.85 | |
| CY2013 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
0.56 | |
| CY2012 | us-gaap |
Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
|
P4Y6M | |
| CY2011 | us-gaap |
Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
|
0.0128 | pure |
| CY2012 | us-gaap |
Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
|
0.0075 | pure |
| CY2013 | us-gaap |
Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
|
0.0036 | pure |
| CY2011 | us-gaap |
Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
|
0 | pure |
| CY2012 | us-gaap |
Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
|
0 | pure |
| CY2013 | us-gaap |
Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
|
0 | pure |
| CY2012 | us-gaap |
Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
|
0.8306 | pure |
| CY2010Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
1300000 | shares |
| CY2011Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
1333000 | shares |
| CY2012Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
1307000 | shares |
| CY2011 | prph |
Stock Issued During Period Stock Options Exercised
StockIssuedDuringPeriodStockOptionsExercised
|
0 | shares |
| CY2012 | prph |
Stock Issued During Period Stock Options Exercised
StockIssuedDuringPeriodStockOptionsExercised
|
0 | shares |
| CY2013 | prph |
Stock Issued During Period Stock Options Exercised
StockIssuedDuringPeriodStockOptionsExercised
|
25000 | shares |
| CY2011 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
187000 | shares |
| CY2012 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
41000 | shares |
| CY2013 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
64000 | shares |
| CY2013Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
1638000 | shares |
| CY2011 | prph |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Subject To Future Vesting Number
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedSubjectToFutureVestingNumber
|
957000 | shares |
| CY2012 | prph |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Subject To Future Vesting Number
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedSubjectToFutureVestingNumber
|
719000 | shares |
| CY2013 | prph |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Subject To Future Vesting Number
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedSubjectToFutureVestingNumber
|
884000 | shares |
| CY2011Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
376000 | shares |
| CY2012Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
588000 | shares |
| CY2013Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
754000 | shares |
| CY2011Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
|
14000 | shares |
| CY2012Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
|
0 | shares |
| CY2013Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
|
262000 | shares |
| CY2010Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
2.99 | |
| CY2011Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
1.88 | |
| CY2012Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
1.72 | |
| CY2011 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
1.10 | |
| CY2013 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
1.64 | |
| CY2011 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
0 | |
| CY2012 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
0 | |
| CY2013 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
1.08 | |
| CY2011 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
8.67 | |
| CY2012 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
8.11 | |
| CY2013 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
4.53 | |
| CY2013Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
1.60 | |
| CY2011 | prph |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Subject To Future Vesting Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedSubjectToFutureVestingWeightedAverageExercisePrice
|
1.02 | |
| CY2012 | prph |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Subject To Future Vesting Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedSubjectToFutureVestingWeightedAverageExercisePrice
|
1.01 | |
| CY2013 | prph |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Subject To Future Vesting Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedSubjectToFutureVestingWeightedAverageExercisePrice
|
1.32 | |
| CY2013Q4 | us-gaap |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
|
753000 | shares |
| CY2013Q4 | us-gaap |
Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
|
1.93 | |
| CY2012 | us-gaap |
Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
|
250000 | USD |
| CY2012Q4 | us-gaap |
Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
|
1.1 | USD |
| CY2011 | prph |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Expected To Be Forfeited
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpectedToBeForfeited
|
33000 | shares |
| CY2012 | prph |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Expected To Be Forfeited
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpectedToBeForfeited
|
0 | shares |
| CY2013 | prph |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Expected To Be Forfeited
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpectedToBeForfeited
|
6 | shares |
| CY2011Q4 | prph |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants In Period Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue
|
127000 | USD |
| CY2012Q4 | prph |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants In Period Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue
|
13000 | USD |
| CY2013Q4 | prph |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants In Period Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue
|
237000 | USD |
| CY2011 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
131000 | USD |
| CY2012 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
153000 | USD |
| CY2013 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
160000 | USD |
| CY2013Q4 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
|
522000 | USD |
| CY2013 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
12000 | USD |
| CY2013 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P2Y3M18D | |
| CY2013Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
678000 | USD |
| CY2013Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
|
465000 | USD |
| CY2013Q4 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
273000 | USD |
| CY2013Q4 | prph |
Sharebased Option Vested During Period
SharebasedOptionVestedDuringPeriod
|
686250 | shares |
| CY2013Q4 | prph |
Sharebased Option Subject To Vesting During Period
SharebasedOptionSubjectToVestingDuringPeriod
|
884250 | shares |
| CY2011 | us-gaap |
Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
|
88000 | USD |
| CY2012 | us-gaap |
Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
|
104000 | USD |
| CY2013 | us-gaap |
Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
|
100000 | USD |
| CY2012 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
759000 | USD |
| CY2013 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
217000 | USD |
| CY2011 | us-gaap |
Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
|
0 | USD |
| CY2012 | us-gaap |
Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
|
0 | USD |
| CY2013 | us-gaap |
Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
|
0 | USD |
| CY2011 | us-gaap |
Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
|
0 | USD |
| CY2012 | us-gaap |
Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
|
0 | USD |
| CY2013 | us-gaap |
Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
|
0 | USD |
| CY2011 | us-gaap |
Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
|
0 | USD |
| CY2012 | us-gaap |
Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
|
0 | USD |
| CY2013 | us-gaap |
Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
|
0 | USD |
| CY2011 | us-gaap |
Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
|
-877000 | USD |
| CY2012 | us-gaap |
Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
|
-618000 | USD |
| CY2013 | us-gaap |
Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
|
1216000 | USD |
| CY2011 | us-gaap |
Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
|
-21000 | USD |
| CY2012 | us-gaap |
Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
|
1377000 | USD |
| CY2013 | us-gaap |
Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
|
-999000 | USD |
| CY2011 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
-898000 | USD |
| CY2011 | prph |
Income Taxes From Continuing Operations Before Valuation Allowance
IncomeTaxesFromContinuingOperationsBeforeValuationAllowance
|
-898000 | USD |
| CY2012 | prph |
Income Taxes From Continuing Operations Before Valuation Allowance
IncomeTaxesFromContinuingOperationsBeforeValuationAllowance
|
759000 | USD |
| CY2013 | prph |
Income Taxes From Continuing Operations Before Valuation Allowance
IncomeTaxesFromContinuingOperationsBeforeValuationAllowance
|
217000 | USD |
| CY2011 | prph |
Income Taxes From Continuing Operations Before Valuation Allowances
IncomeTaxesFromContinuingOperationsBeforeValuationAllowances
|
-898000 | USD |
| CY2012 | prph |
Income Taxes From Continuing Operations Before Valuation Allowances
IncomeTaxesFromContinuingOperationsBeforeValuationAllowances
|
759000 | USD |
| CY2013 | prph |
Income Taxes From Continuing Operations Before Valuation Allowances
IncomeTaxesFromContinuingOperationsBeforeValuationAllowances
|
217000 | USD |
| CY2011 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
-898000 | USD |
| CY2012 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
759000 | USD |
| CY2013 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
217000 | USD |
| CY2011 | us-gaap |
Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items
IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems
|
0 | USD |
| CY2012 | us-gaap |
Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items
IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems
|
0 | USD |
| CY2013 | us-gaap |
Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items
IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems
|
0 | USD |
| CY2011 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
-925000 | USD |
| CY2012 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
-661000 | USD |
| CY2013 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
138000 | USD |
| CY2011 | us-gaap |
Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
|
-21000 | USD |
| CY2012 | us-gaap |
Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
|
1377000 | USD |
| CY2013 | us-gaap |
Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
|
17000 | USD |
| CY2011 | us-gaap |
Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
|
48000 | USD |
| CY2012 | us-gaap |
Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
|
43000 | USD |
| CY2013 | us-gaap |
Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
|
62000 | USD |
| CY2011 | prph |
Income Tax Reconciliation Income Tax Expense Benefit Continuing Operations Before Valuation Allowance
IncomeTaxReconciliationIncomeTaxExpenseBenefitContinuingOperationsBeforeValuationAllowance
|
-898000 | USD |
| CY2012 | prph |
Income Tax Reconciliation Income Tax Expense Benefit Continuing Operations Before Valuation Allowance
IncomeTaxReconciliationIncomeTaxExpenseBenefitContinuingOperationsBeforeValuationAllowance
|
759000 | USD |
| CY2013 | prph |
Income Tax Reconciliation Income Tax Expense Benefit Continuing Operations Before Valuation Allowance
IncomeTaxReconciliationIncomeTaxExpenseBenefitContinuingOperationsBeforeValuationAllowance
|
217000 | USD |
| CY2011 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
898000 | USD |
| CY2012 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-759000 | USD |
| CY2013 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-217000 | USD |
| CY2011 | us-gaap |
Income Tax Reconciliation Nondeductible Expense Meals And Entertainment
IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment
|
2000 | USD |
| CY2012 | us-gaap |
Income Tax Reconciliation Nondeductible Expense Meals And Entertainment
IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment
|
6000 | USD |
| CY2013 | us-gaap |
Income Tax Reconciliation Nondeductible Expense Meals And Entertainment
IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment
|
7000 | USD |
| CY2011 | prph |
Income Tax Reconciliation Non Deductible Expense Return To Accrual For Prior Year Permanent Items
IncomeTaxReconciliationNonDeductibleExpenseReturnToAccrualForPriorYearPermanentItems
|
0 | USD |
| CY2012 | prph |
Income Tax Reconciliation Non Deductible Expense Return To Accrual For Prior Year Permanent Items
IncomeTaxReconciliationNonDeductibleExpenseReturnToAccrualForPriorYearPermanentItems
|
-46000 | USD |
| CY2013 | prph |
Income Tax Reconciliation Non Deductible Expense Return To Accrual For Prior Year Permanent Items
IncomeTaxReconciliationNonDeductibleExpenseReturnToAccrualForPriorYearPermanentItems
|
0 | USD |
| CY2011 | prph |
Income Tax Reconciliation Non Deductible Expense Contribution Of Inventory
IncomeTaxReconciliationNonDeductibleExpenseContributionOfInventory
|
0 | USD |
| CY2012 | prph |
Income Tax Reconciliation Non Deductible Expense Contribution Of Inventory
IncomeTaxReconciliationNonDeductibleExpenseContributionOfInventory
|
4000 | USD |
| CY2013 | prph |
Income Tax Reconciliation Non Deductible Expense Contribution Of Inventory
IncomeTaxReconciliationNonDeductibleExpenseContributionOfInventory
|
1000 | USD |
| CY2011 | us-gaap |
Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
|
46000 | USD |
| CY2012 | us-gaap |
Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
|
79000 | USD |
| CY2013 | us-gaap |
Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
|
54000 | USD |
| CY2011Q4 | prph |
Deferred Tax Assets Operating Loss And Capital Loss Carry Forwards
DeferredTaxAssetsOperatingLossAndCapitalLossCarryForwards
|
13170000 | USD |
| CY2012Q4 | prph |
Deferred Tax Assets Operating Loss And Capital Loss Carry Forwards
DeferredTaxAssetsOperatingLossAndCapitalLossCarryForwards
|
14158000 | USD |
| CY2013Q4 | prph |
Deferred Tax Assets Operating Loss And Capital Loss Carry Forwards
DeferredTaxAssetsOperatingLossAndCapitalLossCarryForwards
|
13569000 | USD |
| CY2011Q4 | prph |
Deferred Tax Assets Consulting Royalty Costs
DeferredTaxAssetsConsultingRoyaltyCosts
|
1431000 | USD |
| CY2012Q4 | prph |
Deferred Tax Assets Consulting Royalty Costs
DeferredTaxAssetsConsultingRoyaltyCosts
|
121000 | USD |
| CY2013Q4 | prph |
Deferred Tax Assets Consulting Royalty Costs
DeferredTaxAssetsConsultingRoyaltyCosts
|
80000 | USD |
| CY2011Q4 | us-gaap |
Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
|
235000 | USD |
| CY2012Q4 | us-gaap |
Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
|
60000 | USD |
| CY2013Q4 | us-gaap |
Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
|
-34000 | USD |
| CY2011Q4 | us-gaap |
Deferred Tax Assets Other
DeferredTaxAssetsOther
|
757000 | USD |
| CY2012Q4 | us-gaap |
Deferred Tax Assets Other
DeferredTaxAssetsOther
|
983000 | USD |
| CY2013Q4 | us-gaap |
Deferred Tax Assets Other
DeferredTaxAssetsOther
|
1009000 | USD |
| CY2011Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
15593000 | USD |
| CY2012Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
15322000 | USD |
| CY2013Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
15056000 | USD |
| CY2011Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
0 | USD |
| CY2012Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
0 | USD |
| CY2013Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
0 | USD |
| CY2011 | us-gaap |
Real Estate Owned Valuation Allowance Amounts Applied
RealEstateOwnedValuationAllowanceAmountsApplied
|
898000 | USD |
| CY2012 | us-gaap |
Real Estate Owned Valuation Allowance Amounts Applied
RealEstateOwnedValuationAllowanceAmountsApplied
|
271000 | USD |
| CY2013 | us-gaap |
Real Estate Owned Valuation Allowance Amounts Applied
RealEstateOwnedValuationAllowanceAmountsApplied
|
266000 | USD |
| CY2012Q1 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
6018000 | USD |
| CY2013Q1 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
7542000 | USD |
| CY2012Q2 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
1894000 | USD |
| CY2013Q2 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
1939000 | USD |
| CY2012Q3 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
5415000 | USD |
| CY2013Q3 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
5949000 | USD |
| CY2012Q4 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
9079000 | USD |
| CY2013Q4 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
9602000 | USD |
| CY2012Q1 | us-gaap |
Gross Profit
GrossProfit
|
4340000 | USD |
| CY2013Q1 | us-gaap |
Gross Profit
GrossProfit
|
5339000 | USD |
| CY2012Q2 | us-gaap |
Gross Profit
GrossProfit
|
825000 | USD |
| CY2013Q2 | us-gaap |
Gross Profit
GrossProfit
|
928000 | USD |
| CY2012Q3 | us-gaap |
Gross Profit
GrossProfit
|
3399000 | USD |
| CY2013Q3 | us-gaap |
Gross Profit
GrossProfit
|
3817000 | USD |
| CY2012Q4 | us-gaap |
Gross Profit
GrossProfit
|
5688000 | USD |
| CY2013Q4 | us-gaap |
Gross Profit
GrossProfit
|
6587000 | USD |
| CY2012Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-688000 | USD |
| CY2013Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
290000 | USD |
| CY2012Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-1930000 | USD |
| CY2013Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-1719000 | USD |
| CY2012Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
1074000 | USD |
| CY2013Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
1237000 | USD |
| CY2012Q4 | us-gaap |
Net Income Loss
NetIncomeLoss
|
453000 | USD |
| CY2013Q4 | us-gaap |
Net Income Loss
NetIncomeLoss
|
597000 | USD |
| CY2012Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.05 | |
| CY2012Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.13 | |
| CY2012Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
0.07 | |
| CY2012Q4 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
0.04 | |
| CY2012Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
548000 | USD |
| CY2013Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
350000 | USD |
| CY2013 | dei |
Document Type
DocumentType
|
10-K | |
| CY2013 | dei |
Amendment Flag
AmendmentFlag
|
false | |
| CY2013 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2013-12-31 | |
| CY2013 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2013 | |
| CY2013 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
FY | |
| CY2013 | dei |
Trading Symbol
TradingSymbol
|
PRPH | |
| CY2014Q1 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
16660324 | shares |
| CY2013 | dei |
Entity Registrant Name
EntityRegistrantName
|
ProPhase Labs, Inc. | |
| CY2013 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0000868278 | |
| CY2013 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
| CY2013 | dei |
Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
|
No | |
| CY2013 | dei |
Entity Voluntary Filers
EntityVoluntaryFilers
|
No | |
| CY2013 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
| CY2013 | dei |
Entity Filer Category
EntityFilerCategory
|
Smaller Reporting Company | |
| CY2013Q2 | dei |
Entity Public Float
EntityPublicFloat
|
15803329 | USD |
| CY2011 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
14817000 | shares |
| CY2012 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
14843000 | shares |
| CY2013 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
16276000 | shares |
| CY2011 | us-gaap |
Interest Expense
InterestExpense
|
0 | USD |
| CY2012 | us-gaap |
Interest Expense
InterestExpense
|
0 | USD |
| CY2013 | us-gaap |
Interest Expense
InterestExpense
|
13000 | USD |
| CY2013 | us-gaap |
Litigation Settlement Interest
LitigationSettlementInterest
|
13000 | USD |
| CY2013Q1 | us-gaap |
Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
|
0.02 | |
| CY2013Q2 | us-gaap |
Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
|
-0.11 | |
| CY2013Q3 | us-gaap |
Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
|
0.08 | |
| CY2013Q4 | us-gaap |
Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
|
0.04 | |
| CY2013Q1 | us-gaap |
Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
|
0.02 | |
| CY2013Q2 | us-gaap |
Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
|
-0.11 | |
| CY2013Q3 | us-gaap |
Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
|
0.08 | |
| CY2013Q4 | us-gaap |
Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
|
0.04 | |
| CY2012 | us-gaap |
Payments For Legal Settlements
PaymentsForLegalSettlements
|
2100000 | USD |
| CY2011 | us-gaap |
Interest Paid
InterestPaid
|
0 | USD |
| CY2012 | us-gaap |
Interest Paid
InterestPaid
|
0 | USD |
| CY2013 | us-gaap |
Interest Paid
InterestPaid
|
13000 | USD |
| CY2013 | us-gaap |
Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
|
100000 | USD |
| CY2013 | prph |
Sharebased Compensation Options Granted Subject To Vesting Date Of Grant Minimum Term
SharebasedCompensationOptionsGrantedSubjectToVestingDateOfGrantMinimumTerm
|
P6Y | |
| CY2013 | prph |
Sharebased Compensation Options Granted Subject To Vesting Date Of Grant Maximum Term
SharebasedCompensationOptionsGrantedSubjectToVestingDateOfGrantMaximumTerm
|
P7Y | |
| CY2012 | prph |
Investory Right To Use Excess Proceeds Maximum Percentage
InvestoryRightToUseExcessProceedsMaximumPercentage
|
0.05 | pure |
| CY2013Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
|
1.31 | |
| CY2013 | us-gaap |
Common Stock Call Or Exercise Features
CommonStockCallOrExerciseFeatures
|
The Rights Agreement, as amended, provides that each Right entitles the stockholder of record to purchase from the Company that number of common shares having a combined market value equal to two times the Rights exercise price of $45.  | |
| CY2013Q4 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
|
884250 | shares |
| CY2013Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
1.31 | |
| CY2011Q4 | us-gaap |
Deferred Tax Assets Investments
DeferredTaxAssetsInvestments
|
0 | USD |
| CY2012Q4 | us-gaap |
Deferred Tax Assets Investments
DeferredTaxAssetsInvestments
|
0 | USD |
| CY2013Q4 | us-gaap |
Deferred Tax Assets Investments
DeferredTaxAssetsInvestments
|
-387000 | USD |
| CY2011Q4 | us-gaap |
Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
|
0 | USD |
| CY2012Q4 | us-gaap |
Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
|
0 | USD |
| CY2013Q4 | us-gaap |
Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
|
819000 | USD |
